Phase 3 N=531 Filtered Trial for Amlodipine Non-responder
Hypertension
Primary: Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing) — 9.56; 4.45 mmHg — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=588 A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)
Postoperative Dental Pain
Primary: Total Pain Relief Score Over the First 6 Hours Post the Initial Day 1 Dose of the Study Medication (TOPAR6) — 5.08; 16.10; 15.73; 15.67 Units on a Scale — p=<0.001
Phase 3 N=801 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
Measles · Mumps · Rubella
Primary: Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer — 322.2; 209.3 gpELISA units/mL
Phase 3 N=50 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Primary Immunodeficiency · Common Variable Hypogammaglobulinemia · X-linked Hypogammaglobulinemia
Primary: Number of Serious, Acute, Bacterial Infections (SABIs) Per Subject Per Year in Subjects With Primary Immunodeficiency Disease. — 0 SABIs/subject/year — p=0.01
Phase 3 N=481 A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined)at 14 Days — 17.72; 17.74; -2.55; -3.60 scores on a scale — p=0.005
Phase 3 N=506 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days — 18.76…
Phase 3 N=536 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days — 17.98; 18.48; -1.97; -3.53 Scores on a scale — p=<0.001
Phase 3 N=394 Tuberculosis Treatment Shortening Trial
Tuberculosis
Primary: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat — 13; 3 Participants
Phase 3 N=154 Somatropin Treatment to Final Height in Turner Syndrome
Turner Syndrome
Primary: Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population — 0.09; 0.97…
Phase 3 N=854 A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy
Hysterectomy · Postoperative
Primary: Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity. — 48.8; 49.0; 52.4; 52.9 units on scale — p=<0.0001
Phase 3 N=113 A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20) — 65.5; 42.1 percentage of participants
Phase 3 N=332 Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
Postmenopausal Osteoporosis
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 — 6.5; -.6 Percent Change from Baseline — p=<0.0001
Phase 3 N=120 Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Ankle Score to the End of the DB Phase (Week 12) — -8.513; -5.085 Score*week…
Phase 3 N=252 AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
Breast Cancer · Low Bone Mineral Density · Osteopenia
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — 4.8; -.7 Percent Change from Baseline — p=<0.0001
Phase 3 N=151 Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 12 Week Endpoint…